Skip to main
PRE
PRE logo

PRE Stock Forecast & Price Target

PRE Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 27%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Prenetics Global Ltd has demonstrated a remarkable year-over-year revenue increase of 59% in its 3Q24 results, reaching $7.8 million, primarily driven by strong performance from its ACT Genomics and CircleDNA divisions. The company achieved significant operational improvements, with gross margins rising to 51.8%, up from 33.9% the previous year, attributed to enhanced pricing strategies and cost optimization efforts. Additionally, Prenetics anticipates that its CircleDNA and ACT Genomics units will reach business-unit break-even by the second half of 2024, ahead of prior expectations, which further underscores the potential for future profitability and growth.

Bears say

The financial outlook for Prenetics Global Ltd has been negatively impacted by a reduction in revenue estimates for CY24 and CY25, with projections decreasing to $32.5 million and $75.4 million, respectively, due to a disappointing performance in 3Q24 and a strategic shift towards the IM8 initiative. Additionally, the company reported an operating loss of approximately $11.8 million in 3Q24, which, while slightly improved from the prior year's loss of $13.0 million, still highlights underlying financial challenges. Overall, these factors contribute to a cautious view regarding Prenetics' future profitability and revenue growth potential.

PRE has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 27% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prenetics Global Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prenetics Global Ltd (PRE) Forecast

Analysts have given PRE a Hold based on their latest research and market trends.

According to 11 analysts, PRE has a Hold consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prenetics Global Ltd (PRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.